Clinical Trial Update: Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali [Phase 2]

View source ↗

Summary

Phase 2 trial of the Pfs230D1M-EPA/AS01 malaria transmission-blocking vaccine in Mali (children and family compound setting) has completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pfs230D1M-EPA/AS01 vaccine (Pfs230D1M-EPA/AS01)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2022-08-23